VALIDATION OF AN ALGORITHM TO IDENTIFY HR+/HER2-METASTATIC BREAST CANCER IN CLAIMS DATA

被引：0
|
作者：
Chin, A. [1 ]
Ip, Q. [1 ]
Wu, X. [1 ]
Lyle, D. [2 ]
机构：
[1] Komodo Hlth, San Francisco, CA USA
[2] NeoGenomics, Ft Myers, FL USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EPH56
引用
收藏
页码：S163 / S163
页数：1
相关论文
共 50 条
  • [1] Abemaciclib in HR+/HER2-metastatic breast cancer: A realworld experience
    Bottosso, M.
    Giarratano, T.
    Barbieri, C.
    Menichetti, A.
    Cumerlato, E.
    Miglietta, F.
    Genovesi, E.
    Amato, O.
    Dieci, M. V.
    Griguolo, G.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S73 - S74
  • [2] HEALTHCARE RESOURCE USE AND COSTS OF CARE IN HR+/HER2-METASTATIC BREAST CANCER: A RETROSPECTIVE US CLAIMS DATA STUDY
    Collin, S.
    Tse, J.
    Shaikh, N. F.
    Near, A.
    Hamilton, E.
    Brufsky, A.
    Gradishar, W.
    Mehta, S.
    Long, G. H.
    Toms, N.
    VALUE IN HEALTH, 2024, 27 (06) : S134 - S134
  • [3] Experience with eribulin in HR+/HER2-metastatic breast cancer, including a male
    Munoz Sanchez, Maria del Mar
    Soriano Rodriguez, Maria del Carmen
    Molina Garrido, Maria Jose
    Lopez-Gonzalez, Ana
    Garcia-Palomo, Andres
    Lopez-Gonzalez, Laura
    Plata Fernandez, Maria Yessica
    Luque Caro, Natalia
    Sanchez Rovira, Pedro
    FUTURE ONCOLOGY, 2018, 14 (07) : 5 - 12
  • [4] Sacituzumab govitecan in HR+ and HER2-metastatic breast cancer: for all or for some?
    Loibl, Sibylle
    Holtschmidt, Johannes
    LANCET, 2023, 402 (10411): : 1394 - 1395
  • [5] Physician survey in the treatment of HR+/HER2-metastatic breast cancer in Egypt
    Aboelkheir, E.
    Ashour, A.
    Fadel, S.
    Arafat, W.
    BREAST, 2021, 56 : S31 - S31
  • [6] Everolimus-based combination therapies for HR+, HER2-metastatic breast cancer
    O'Shaughnessy, Joyce
    Beck, J. Thaddeus
    Royce, Melanie
    CANCER TREATMENT REVIEWS, 2018, 69 : 204 - 214
  • [7] Cost of recurrence among patients with HR+/HER2-metastatic breast cancer.
    Engel-Nitz, Nicole M.
    Becker, Laura
    Gerdes, Randall
    Hao, Yanni
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Clinical outcomes among HR+/HER2-metastatic breast cancer patients with multiple metastatic sites
    Xie, J.
    Hao, Y.
    Li, N.
    Lin, P. L.
    Ohashi, E.
    Koo, V.
    Wu, E. Q.
    CANCER RESEARCH, 2016, 76
  • [9] HR+/HER2-metastatic Breast Cancer Increasing Data Density of CDK4/6 Inhibitors
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (09) : 485 - 485
  • [10] Time on treatment of everolimus, fulvestrant, and capecitabine for the treatment of HR+/HER2-metastatic breast cancer: A retrospective claims study in the US
    Li, N.
    Hao, Y.
    Kageleiry, A.
    Peeples, M.
    Fang, A.
    Koo, V.
    Guerin, A.
    CANCER RESEARCH, 2016, 76
12345